Paper28656259
Anti-angiogenesis target therapy for advanced osteosarcoma (Review).
Xie L and 2 others. Oncol Rep, 2017. Cited by 94 papers, by iCite.
Cite this record
ConductScience Library. Anti-angiogenesis target therapy for advanced osteosarcoma (Review). Papers, record 28656259. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28656259
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lung Neoplasms | Major topic |
| Neovascularization, Pathologic | Major topic |
| Osteosarcoma | Major topic |
| Disease-Free Survival | |
| Gene Expression Regulation, Neoplastic | |
| Humans | |
| Neoplasm Metastasis | |
| Neoplasm Staging | |
| Vascular Endothelial Growth Factor A | |
| Vascular Endothelial Growth Factor Receptor-1 |
Source PubMed
References119
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21527590 | A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. | Ann Oncol | 2012 | https://conductscience.org/library/papers/21527590 | PubMed |
| 2 | 16809160 | Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. | Cancer Invest | 2006 | https://conductscience.org/library/papers/16809160 | PubMed |
| 3 | 16226705 | Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. | Cancer Cell | 2005 | https://conductscience.org/library/papers/16226705 | PubMed |
| 4 | 15479481 | Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. | Clin Colorectal Cancer | 2004 | https://conductscience.org/library/papers/15479481 | PubMed |
| 5 | 23589053 | A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. | Tumour Biol | 2013 | https://conductscience.org/library/papers/23589053 | PubMed |
| 6 | 22669161 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. | Br J Cancer | 2012 | https://conductscience.org/library/papers/22669161 | PubMed |
| 7 | 21495021 | Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. | Cancer | 2011 | https://conductscience.org/library/papers/21495021 | PubMed |
| 8 | 25126591 | Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis. | Oncoscience | 2014 | https://conductscience.org/library/papers/25126591 | PubMed |
| 9 | 26330427 | New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/26330427 | PubMed |
| 10 | 20003259 | Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. | Mol Cancer | 2009 | https://conductscience.org/library/papers/20003259 | PubMed |
| 11 | 26440568 | Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors. | Nucl Med Commun | 2016 | https://conductscience.org/library/papers/26440568 | PubMed |
| 12 | 20842228 | Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. | J Cancer | 2010 | https://conductscience.org/library/papers/20842228 | PubMed |
| 13 | 12177445 | VEGF-Trap: a VEGF blocker with potent antitumor effects. | Proc Natl Acad Sci U S A | 2002 | https://conductscience.org/library/papers/12177445 | PubMed |
| 14 | 19261927 | High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. | Radiology | 2009 | https://conductscience.org/library/papers/19261927 | PubMed |
| 15 | 24613529 | Anti-angiogenic therapy, a new player in the field of sarcoma treatment. | Crit Rev Oncol Hematol | 2014 | https://conductscience.org/library/papers/24613529 | PubMed |
| 16 | 26291057 | Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. | Br J Cancer | 2015 | https://conductscience.org/library/papers/26291057 | PubMed |
| 17 | 25145405 | Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer. | Acta Med Okayama | 2014 | https://conductscience.org/library/papers/25145405 | PubMed |
| 18 | 17942672 | Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. | Proc Natl Acad Sci U S A | 2007 | https://conductscience.org/library/papers/17942672 | PubMed |
| 19 | 15985268 | Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. | Life Sci | 2005 | https://conductscience.org/library/papers/15985268 | PubMed |
| 20 | 11357143 | Oncogenic kinase signalling. | Nature | 2001 | https://conductscience.org/library/papers/11357143 | PubMed |
Cited by62
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41553639 | Aging reshapes the osteosarcoma ecosystem through immune dysfunction and tumor cell reprogramming. | Cell Oncol (Dordr) | 2026 | https://conductscience.org/library/papers/41553639 | PubMed |
| 41395622 | Efficacy and safety of anlotinib for the treatment of advanced bone and soft tissue sarcomas: a systematic review and meta-analysis. | Front Oncol | 2025 | https://conductscience.org/library/papers/41395622 | PubMed |
| 41301872 | Biomimetic Porous Coatings on a Biocompatible Ti-15Mo Alloy as a Platform for Local Delivery of Anticancer Drugs to Patient Tissues. | Biomedicines | 2025 | https://conductscience.org/library/papers/41301872 | PubMed |
| 40989695 | Identification of MAEA protein as a potential target for chemoresistance in osteosarcoma using bioinformatics and proteomic analysis. | Front Oncol | 2025 | https://conductscience.org/library/papers/40989695 | PubMed |
| 40676851 | Pathobiology and Molecular Pathways Implicated in Osteosarcoma Lung Metastasis: A Scoping Review. | Technol Cancer Res Treat | 2025 | https://conductscience.org/library/papers/40676851 | PubMed |
| 39769419 | Whole-Exome Analysis and Osteosarcoma: A Game Still Open. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39769419 | PubMed |
| 39252946 | Targeted anti-angiogenesis therapy for advanced osteosarcoma. | Front Oncol | 2024 | https://conductscience.org/library/papers/39252946 | PubMed |
| 38948019 | Exploring the effects of taurolidine on tumor weight and microvessel density in a murine model of osteosarcoma. | Oncol Res | 2024 | https://conductscience.org/library/papers/38948019 | PubMed |
| 38835052 | System analysis based on Anoikis-related genes identifies MAPK1 as a novel therapy target for osteosarcoma with neoadjuvant chemotherapy. | BMC Musculoskelet Disord | 2024 | https://conductscience.org/library/papers/38835052 | PubMed |
| 37404767 | Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma. | Front Oncol | 2023 | https://conductscience.org/library/papers/37404767 | PubMed |
| 37377920 | A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma. | Front Oncol | 2023 | https://conductscience.org/library/papers/37377920 | PubMed |
| 37300290 | SP-8356 (A Verbenone Derivative) Inhibits Proliferation, Suppresses Cell Migration and Invasion and Decreases Tumor Growth of Osteosarcoma: Role of PGC-1α/TFAM and AMPK-Activation. | Cell J | 2023 | https://conductscience.org/library/papers/37300290 | PubMed |
| 36983138 | Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients. | J Clin Med | 2023 | https://conductscience.org/library/papers/36983138 | PubMed |
| 36944946 | Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. | J Nanobiotechnology | 2023 | https://conductscience.org/library/papers/36944946 | PubMed |
| 36765658 | Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36765658 | PubMed |
| 36759884 | Abnormal signal pathways and tumor heterogeneity in osteosarcoma. | J Transl Med | 2023 | https://conductscience.org/library/papers/36759884 | PubMed |
| 36632464 | Ebastine exerts antitumor activity and induces autophagy by activating AMPK/ULK1 signaling in an IPMK-dependent manner in osteosarcoma. | Int J Biol Sci | 2023 | https://conductscience.org/library/papers/36632464 | PubMed |
| 36618348 | Comprehensive analysis of a glycolysis and cholesterol synthesis-related genes signature for predicting prognosis and immune landscape in osteosarcoma. | Front Immunol | 2022 | https://conductscience.org/library/papers/36618348 | PubMed |
| 36177059 | The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis. | Biomed Res Int | 2022 | https://conductscience.org/library/papers/36177059 | PubMed |
| 36176756 | An overview of resistance to chemotherapy in osteosarcoma and future perspectives. | Cancer Drug Resist | 2022 | https://conductscience.org/library/papers/36176756 | PubMed |
Genes40
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28656259
GET https://conductscience.org/api/papers/v1/28656259/references?page=2